Evidence map›Paper›PMID 41312930›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2025

High Expression of Actin Binding Proteins Predicts Hematogenous Metastases in Non-Small Cell Lung Cancer.

Elena S Kolegova, Gelena V Kakurina, Elena E Sereda, Evgenia A Sidenko, Dmitriy N Kostromitskiy, Alexey Yu Dobrodeev, Irina V Kondakova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elena S KolegovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.
Gelena V KakurinaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0002-4506-9429
Elena E SeredaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.
Evgenia A SidenkoCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-5838-9459
Dmitriy N KostromitskiyCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-5691-2349
Alexey Yu DobrodeevCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.
Irina V KondakovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0003-0907-4615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe high mortality rate in non-small cell lung cancer (NSCLC) patients is associated with tumor progression. Tumor cell motility, which is mediated by various actin-binding proteins (ABPs) plays a crucial role in tumor progression. Therefore, the study of the relationship between the expression of ABPs (CAP1, cofilin-1, profilin-1, fascin-1 and ezrin) and NSCLC progression is of great significance.

methodsNSCLC tissue samples and tumor-adjacent unchanged lung tissue samples were collected from 46 NSCLC patients who were not previously treated. The mRNA expression of ABPs was determined by real-time PCR, and the ABP expression was analyzed using Western blotting assay.

resultsAll ABPs showed the correlation with 2-year metastasis-free survival. The increased mRNA levels of САР1, CFL1, EZR, FSCN1 and PFN1 and their protein products in tumor tissue compared to tumor-adjacent unchanged tissue indicated the risk of hematogenous metastases.

conclusionThe data obtained demonstrated the feasibility of using these ABPs as additional predictors of  NSCLC prognosis.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsMicrofilament ProteinsAgedCarrier ProteinsCell Cycle ProteinsCofilin 1Cytoskeletal ProteinsEzrinFemaleFollow-Up StudiesHumansMaleMiddle AgedBiomarkers, TumorCAP1 protein, humanCarrier ProteinsCell Cycle ProteinsCFL1 protein, humanCofilin 1Cytoskeletal ProteinsEzrinFSCN1 protein, humanMicrofilament ProteinsPFN1 protein, humanProfilinsRNA, Messengeractin-binding proteinsMetastasisnon-small cell lung cancerprogression

Identifiers

PMID41312930
PMCPMC12936129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.